chtl-1 Antibody
Description
Research Applications of Anti-CTL1 Antibodies
Anti-CTL1 antibodies like ACT-021 (#ACT-021, Alomone Labs) are widely used in:
-
Flow cytometry: Detects extracellular CTL1 in live human leukemia cell lines (e.g., THP-1, Jurkat) .
-
Western blot: Identifies CTL1 in mouse, rat, and human samples .
-
Functional studies: Links CTL1 deficiency to neurodegenerative pathologies and cancer .
Key Validation Data:
Neurodegenerative Disorders
CTL1 deficiency reduces choline transport, leading to:
-
Cellular effects: Phosphatidylcholine depletion, mitochondrial dysfunction, and impaired membrane integrity .
-
Clinical manifestations: Ataxia, cognitive decline, and leukoencephalopathy .
Cancer Biology
-
Overexpression: Associated with monocytic differentiation and dendritic cell maturation .
-
Metabolic reprogramming: Supports phospholipid synthesis in malignancies .
Comparative Analysis of Anti-CTL1 Antibodies
Note: CHL-1/L1CAM-2 and SLC5A7 antibodies target distinct proteins unrelated to CTL1 but are included for clarity .
Therapeutic Implications
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
Based on the analysis of recent research on HTLV-1 antibodies and their role in disease pathology, here are structured FAQs addressing key academic research considerations:
Advanced Research Questions
How can contradictory findings about CTL efficacy in HTLV-1 control be resolved?
Early studies suggested HTLV-1-specific CTLs were ineffective at reducing proviral load , but later work identified CTL functional avidity as a critical determinant:
What strategies improve predictive models for HTLV-1-associated disease risk?
A 2023 study developed a combined biomarker model :
This model achieved 89% accuracy in identifying carriers with pre-leukemic mutations .
Why do antibodies against conformational vs linear epitopes show divergent clinical correlations?
-
Conformational epitopes (e.g., gp46 VLPs): Neutralizing antibodies correlate with protection against ATL progression .
-
Linear epitopes (e.g., denatured L1): Higher titers associate with advanced cervical lesions in HPV co-infections but lack neutralizing capacity .
Experimental design must specify antigen preparation methods (e.g., baculovirus-derived VLPs vs denatured proteins) .
Methodological Challenges
How to address batch variability in polyclonal antibody reagents for HTLV-1 research?
-
Use recombinant monoclonal antibodies for consistent epitope targeting .
-
Validate cross-reactivity using:
